Fig. 3. Treatment with eSLC-hCXCL16^K42A provides systemic therapeutic benefit.

(A) Tumor growth curve of untreated tumor from BALB/c mice (n ≥ 5 per group) implanted subcutaneously with A20 cells on both hind flanks that received intratumoral injections (black arrows) of the indicated strain into a single tumor. Data are representative of two independent experiments (***P < 0.001, two-way ANOVA with Holm-Sidak post hoc test). (B) Colony-forming unit (CFU) analysis in BALB/c mice (n = 4 per group) treated as in (A). Data are representative of two independent experiments. (C) Flow cytometric analysis of tumor-infiltrating lymphocytes isolated from untreated subcutaneous A20 tumors (n ≥ 4 mice per group) on day 8 following treatment with the indicated strain. Frequencies of intratumoral Granzyme-B⁺CD8⁺ T cells. Data are representative of two independent experiments. *P < 0.05 and **P < 0.01, one-way ANOVA with Holm-Sidak post hoc test. (D) Tumor growth curves of BALB/c mice (n ≥ 5 per group) injected with A20 cells into both hind flanks that received a single intravenous (I.V.) injection (black arrow) of the indicated strain. Data are representative of two independent experiments (****P < 0.0001, two-way ANOVA with Holm-Sidak post hoc test). (E) CFU analysis in BALB/c mice (n = 3 per group) treated as in (D). (F and G) Tumor growth curves and weights of BALB/c mice (n ≥ 4 per group) that were injected with A20 cells into both hind flanks and received a single intravenous injection (black arrow) of the indicated treatment. (F) **P < 0.01, two-way ANOVA with Holm-Sidak post hoc test; (G) *P < 0.05, **P < 0.01, and ***P < 0.001, one-way ANOVA with Holm-Sidak post hoc test. Data are displayed as means ± SEM. LN, lymph node.